The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and pharmacokinetics, with ...

ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT Development of both the prostate cancer ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

Qingdao Putaike Biomedical Technology Co. Ltd. has described androgen receptor full length (AR-FL) and/or androgen receptor variant 7 (AR-v7) degradation inducers reported to be useful for the ...

SaveHealth provides an overview of DHT shampoos, including pros, cons, and what kinds of issues they best solve.

Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further expanding its portfolio of liquid biopsy solutions and strengthening its position ...

"The clinical promise of pocenbrodib, our potential best-in-class CBP/p300 inhibitor, lies not only in its remarkable efficacy in resistant prostate cancer models, but also in our sophisticated ...

Monte Rosa Therapeutics' stock falls as MRT-2359 faces challenges in targeting CRPC. Click here to read an analysis of GLUE ...

by binding to a receptor called the androgen receptor (AR). However, it has remained unclear which cells in skeletal muscle are targeted by androgen and by what mechanism of action it regulates ...